<DOC>
	<DOC>NCT00002200</DOC>
	<brief_summary>The purpose of this study is to see if it is safe and effective to give 1592U89 to HIV-positive adults. This study also examines the influence previous anti-HIV treatment has on the effectiveness of 1592U89.</brief_summary>
	<brief_title>A Study of 1592U89 in HIV-Infected Adults</brief_title>
	<detailed_description>Patients receive open-label 1592U89 administered orally in combination with at least one other antiretroviral agent that the patient has not previously received.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication: Allowed: Erythropoietin, GCSF and GMCSF. Patients must have: CD4+ cell count &lt; 100 cells/mm3. HIV1 RNA &gt; 30,000 copies/ml. Signed, informed consent from parent or legal guardian for patient under 18 years of age. Exclusion Criteria Coexisting Condition: Patients with the following conditions or symptoms are excluded: Renal failure requiring dialysis. Hepatic failure evident by grade 3/4 hyperbilirubinemia and AST 5 times the upper limit of normal. Documented hypersensitivity to 1592U89. Serious medical conditions, such as diabetes, congestive heart failure, cardiomyopathy, or other cardiac dysfunction, that would compromise the safety of the patient. Participation in or ability to participate in an enrolling study of 1592U89. Required: At least 2 nucleoside reverse transcriptase inhibitors (NRTI) and one protease inhibitor (or intolerance to one protease inhibitor and one NRTI due to trying at least 2 different regimens with at least one protease inhibitor). Alcohol or illicit drug use that may interfere with the patient's compliance.</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1998</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Administration, Oral</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>RNA, Viral</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>abacavir</keyword>
</DOC>